Joshua Pinto named Neumora Therapeutics CEO as Paul Berns moves to executive chair role

Joshua Pinto named Neumora Therapeutics CEO as Paul Berns moves to executive chair role
Neumora Therapeutics names new CEO

Neumora Therapeutics announced today the appointment of Joshua Pinto, Ph.D., as the new chief executive officer and member of the Board of Directors.

The leadership change coincided with the company’s release of its second quarter 2026 financial results. Paul L. Berns, the outgoing CEO, will transition to the role of Executive Chair. The company did not provide additional details regarding its financial performance within the announcement. Further information is available on the Neumora Therapeutics website.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.